A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
With
The Leukemia and Lymphoma Society
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults age ≥ 18 years
* Multilineage bone marrow failure
* Serum creatinine ≤ 2.0 mg/dl
* Hepatic enzymes (AST, ALT) ≤ 3x upper limit of normal (ULN)
* Bilirubin ≤ 2.0 mg/dl, unless due to Gilbert's disease, hemolysis or leukemic infiltration
* Left ventricular ejection fraction ≥ 45%
* QTc ≤ 470 msec
* RB expression is required for the action of PD 0332991. Because rb deletions and mutations are rare in acute leukemias and MDS, screening for RB expression will not be required before enrollment. Pretreatment biopsies will be stored and analyzed for RB expression if needed subsequently.
You may not be if
• No more than 5 cytotoxic regimens
* Previous allogeneic or autologous stem cell transplantation permitted
* ≥ 3 weeks delay from prior cytotoxic chemotherapy or radiation therapy
* ≥ 2 week delay from prior biologic therapies including hematopoietic growth factors and vidaza or decitabine
* If using Hydroxyurea, steroids, tyrosine kinase/src kinase inhibitors, arsenic, interferon for count control, must be off therapy for ≥ 48 hours prior to beginning PD 0332991
* No concomitant use of potent CYP450 3A4 inhibitors (e.g. triazole antifungal agents) or inducers (e.g. omperazole, dilantin, dexamethasone) within 7 days prior to beginning PD 0332991
Clareo Health | A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
